MigraineMind research summary
Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project).
Cephalalgia | 2026
Observational studySummary
Rimegepant is a CGRP receptor antagonist for treating episodic migraines. This study examined rimegepant's effectiveness in patients with previous treatment failures. It was conducted across nine headache units in Spain. A total of 150 patients started rimegepant for migraine prevention. Patients were followed for up to six months. The main goal was to see changes in monthly headache days. At three months, median monthly headache days dropped from 12 to 7.5. Monthly migraine days also decreased from 10 to 6. About 36% achieved a 50% reduction in headache days. Among those with six-month data, improvements continued, showing 48% response rates. Rimegepant was well tolerated, with mild side effects like nausea in 13%. Low discontinuation rate was 7% at three months. The study suggests rimegepant may work better with early use, especially in treatment-resistant patients. Clinical relevance: This research highlights rimegepant's potential benefits for patients with treatment-resistant migraines.
Key Learning Points
- Rimegepant is effective for patients with episodic migraines who have not responded to previous treatments.
- Patients experienced a significant reduction in monthly headache days after starting rimegepant.
- Approximately 36% of patients achieved at least a 50% reduction in headache days within three months.
- Rimegepant was generally well tolerated, with mild side effects reported in a small percentage of patients.
- Early use of rimegepant may provide better outcomes for those with treatment-resistant migraines.
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.